首页> 外文期刊>Molecular & cellular proteomics: MCP >Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer.
【24h】

Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer.

机译:膀胱癌相关蛋白,人膀胱癌的潜在预后生物标志物。

获取原文
获取原文并翻译 | 示例
           

摘要

It is becoming increasingly clear that no single marker will have the sensitivity and specificity necessary to be used on its own for diagnosis/prognosis of tumors. Interpatient and intratumor heterogeneity provides overwhelming odds against the existence of such an ideal marker. With this in mind, our laboratory has been applying a long term systematic approach to identify multiple biomarkers that can be used for clinical purposes. As a result of these studies, we have identified and reported several candidate biomarker proteins that are deregulated in bladder cancer. Following the conceptual biomarker development phases proposed by the Early Detection Research Network, we have taken some of the most promising candidate proteins into postdiscovery validation studies, and here we report on the characterization of one such biomarker, the bladder cancer-associated protein (BLCAP), formerly termed Bc10. To characterize BLCAP protein expression and cellular localization patterns in benign bladder urothelium and urothelial carcinomas (UCs), we used two independent sets of samples from different patient cohorts: a reference set consisting of 120 bladder specimens (formalin-fixed as well as frozen biopsies) and a validation set consisting of 2,108 retrospectively collected UCs with long term clinical follow-up. We could categorize the UCs examined into four groups based on levels of expression and subcellular localization of BLCAP protein and showed that loss of BLCAP expression is associated with tumor progression. The results indicated that increased expression of this protein confers an adverse patient outcome, suggesting that categorization of staining patterns for this protein may have prognostic value. Finally, we applied a combinatorial two-marker discriminator using BLCAP and adipocyte-type fatty acid-binding protein, another UC biomarker previously reported by us, and found that the combination of the two markers correlated more closely with grade and/or stage of disease than the individual markers. The implications of these results in biomarker discovery are discussed.
机译:越来越清楚的是,没有单一标记物具有单独用于肿瘤诊断/预后所必需的敏感性和特异性。患者之间和肿瘤内的异质性为这种理想标记物的存在提供了压倒性的机会。考虑到这一点,我们的实验室一直在采用长期的系统方法来鉴定可用于临床目的的多种生物标志物。这些研究的结果是,我们已经鉴定并报道了几种在膀胱癌中失控的候选生物标志物蛋白。在早期检测研究网络提出的概念性生物标志物开发阶段之后,我们将一些最有前途的候选蛋白用于发现后验证研究,在这里我们报告了一种这样的生物标志物,即膀胱癌相关蛋白(BLCAP)的表征。 ,以前称为Bc10。为了表征良性膀胱尿路上皮癌和尿路上皮癌(UCs)中BLCAP蛋白的表达和细胞定位模式,我们使用了两组来自不同患者队列的独立样本:一组由120份膀胱标本组成的参考样本(福尔马林固定和冷冻活检)验证集由2108例回顾性收集的UC组成,并进行了长期的临床随访。我们可以根据表达水平和BLCAP蛋白的亚细胞定位将被检查的UC分为四类,并显示BLCAP表达的丧失与肿瘤的进展有关。结果表明,该蛋白表达的增加赋予患者不利的结局,表明该蛋白的染色模式分类可能具有预后价值。最后,我们使用BLCAP和脂肪细胞型脂肪酸结合蛋白(我们先前报道的另一种UC生物标志物)应用了组合的两标志物鉴别器,发现这两种标志物的组合与疾病的等级和/或阶段更紧密相关比单个标记讨论了这些结果在生物标志物发现中的意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号